In summary, these findings indicate that FMT holds promise in treating PD by mitigating inflammation via TLR4/TNF-α signaling pathway inhibition, improving mitochondrial damage through AMPK/SOD2 pathway activation, and reducing oxidative stress via NMNAT2 upregulation. Here, TLR4 is linked to Parkinson disease.